Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
141
resultados
Última actualización
23/08/2025 [06:58:00]
Resultados 75 a 100 de 141
Resumen de: US2025222201A1
Techniques disclosed herein relate to infusion devices and alerts. In some embodiments, the techniques may involve determining an expected glucose measurement value after delivery of a correction bolus based on an amount of the correction bolus and a current amount of active insulin in a body of a patient. The techniques may further involve obtaining a current glucose measurement value. The techniques may further involve detecting an anomalous response to the correction bolus responsive to determining that a difference between the current glucose measurement value and the expected glucose measurement value exceeds a predetermined threshold.
Resumen de: WO2025147163A1
The present disclosure relates to an artificial intelligence-based apparatus and method for pancreatic frozen section examination and diagnosis. The apparatus comprises: a memory; and a processor including an artificial intelligence engine for the pancreatic frozen section examination and diagnosis, wherein the processor can acquire a first frozen section image of the pancreas, acquire a second frozen section image corresponding to the first frozen section image of the pancreas, and generate and provide a diagnosis result for the pancreatic frozen section examination on the basis of the first frozen section image and the second frozen section image by using the artificial intelligence engine.
Resumen de: US2025221674A1
Systems and methods for monitoring glucose variability in a subject are described. Data indicative of glucose levels of the subject is received from a sensor control device. A first glucose variability metric of the subject in a first time period is determined. The first glucose variability metric may be compared to a threshold. A first indicator is displayed if the first glucose variability metric does not exceed the threshold and a second indicator is displayed if the first glucose variability metric exceeds the threshold. Additional glucose variability metrics may be determined for subsequent time periods according to a rolling window, and the indicators may be displayed real time or in a report. The glucose variability metric may be a measure of variability compared to a baseline, a difference between a maximum and minimum glucose level, or time in or out of a target range.
Resumen de: WO2025146479A1
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time- correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Resumen de: US2025221637A1
This invention provides a coin-sized, fully integrated and wearable continuous glucose monitoring system (CGMs) via combining cutting-edge technologies from the intersecting fields of biosensors, minimally invasive tools, and hydrogels. The invention includes three major parts: 1) an emerging biochemical amplifier, the organic electrochemical transistor (OECT), to improve sensitivity beyond traditional electrochemical modules; 2) a microneedle array for interstitial-fluid (ISF) sampling with reduced pain during skin penetration; and 3) a tough, adhesive enzymatic-hydrogel-membrane to enhance reliability of glucose sensing on skin. Unlike conventional CGMs, the employed OECT amplifier empowers the CGM (OECT-CGMs) with a high anti-noise ability, an on-demand-tunable sensitivity and current regeneration ability, enabling long-term stable glucose sensing within specific clinical ranges (1 ̃20 mM). This work paves the way for the development of next-generation CGMs that can simultaneously deliver high and adjustable sensitivity, minimal invasiveness, and improved wearability.
Resumen de: US2025221639A1
Systems and methods for monitoring glucose levels of a user are described. Data indicative of glucose levels of the subject is received. A count is assigned for each glucose episode based at least on an area under the curve of the each glucose episode in a dataset of time-correlated glucose data. A running sum of counts for each glucose episode in a time period is calculated. The running sum of the counts may be displayed in a numerator of a fraction and a target count goal in a denominator of the fraction. A progress indicator representative of the running sum of the counts relative to a target count goal for the time period may also be displayed. A length of a variable portion may be proportional to the running sum of the counts, and a total length of the progress indicator may be proportional to the target count goal.
Resumen de: US2025221673A1
Systems and methods for predictive glucose in accordance with embodiments of the invention are illustrated. One embodiment includes glucose management device, including a brain signal recorder, and a controller, including a processor, and a memory, the memory containing a glucose monitoring application configured to direct the processor to record a brain activity signal of a user's brain using the brain signal recorder, and decode the brain activity signal to predict future glucose levels of the patient.
Resumen de: CN119731745A
Systems and methods for determining a glucose value of a user are disclosed herein. The method includes: receiving a plurality of data inputs associated with biometric data of a user, the plurality of data inputs including at least one data input representing past estimated glucose values of the user; and processing the plurality of data inputs with a multi-head temporal convolutional neural network to generate a blood glucose value for the user. The method further includes providing a notification to the user based at least in part on the blood glucose value.
Resumen de: AU2025204350A1
Peritoneal dialysis, such as automated peritoneal dialysis (“APD”) is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient’s peritoneal cavity. Peritoneal dialysis, such as automated peritoneal dialysis ("APD") is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient's peritoneal cavity. un u n e r i t o n e a l d i a l y s i s , s u c h a s a u t o m a t e d p e r i t o n e a l d i a l y s i s ( " " ) i s p r o v i d e d w i t h a n y o n e o r m o r e o r a l l o f t h e f o l l o w i n g s e n s i n g o r f e e d b a c k f e a t u r e s : i m p e d a n c e s e n s i n g t o d e t e c t p e r i t o n i t i s , t e m p e r a t u r e s e n s i n g t o d e t e c t p e r i t o n i t i s , b i o - s e n s i n g t o d e t e c t p e r i t o n i t i s , a n d g l u c o s e c o n t r o l f o r d i a b e t e s p a t i e n t s , w h e r e i n e a c h s e n s i n g o r f e e d b a
Resumen de: WO2025141628A1
This blood glucose level measurement device comprises: a sensor unit that measures the blood glucose level of a user; a communication unit that transmits, to the outside, data representing the blood glucose level measured by the sensor unit; a flexible, sheet-shaped battery that supplies power to the sensor unit and the communication unit; a flexible, plate-shaped circuit unit that controls the operation of the communication unit; and a mounting unit that is configured to be mounted on the body of the user. The peak current of the battery is 20 mA or more.
Resumen de: WO2025143904A2
Disclosed is an RF biosensing system using an RF sensor including a glucose-responsive hydrogel-based microneedle. The RF biosensing system measures a sensing signal with a VNA by detecting a sensing signal by using a reader antenna and a reader antenna sensing circuit through a readout coil on the basis of RF biosensing and wireless transmission, via EM coupling between a glucose-responsive hydrogel-based microneedle, which is provided below a flexible substrate so as to be minimally invasively applied in vivo to the skin surface (on-site) of epidermis/dermis/hypodermis of the skin or to skin/fat/muscle tissue, and an RF sensor, which is positioned over the flexible substrate and uses the difference in resonant frequencies within frequencies of 400 to 3,000 MHz, and performs biosensing such as detection of proteins, glucose, and fat in the skin, on the basis of changes in the capacitance of a sensing antenna circuit (LC resonator) of the RF sensor, shifts in resonant frequencies of the LC resonator, and changes in S-parameters.
Resumen de: WO2025144547A1
A continuous analyte monitoring system includes analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller is coupled to the analyte sensors and configured evaluate first samples of outputs of a first analyte sensor and second samples of outputs of a second analyte sensor to determine whether the first samples and the second samples indicate compression of the tissue. The controller compensates for the compression of the tissue with respect to the first samples. A force sensor may be used and may be positioned between a circuit board and a housing, the circuit board supported by supports providing preloading of the force sensor. A force deflector may be used to direct loads away from tissue holding the analyte sensors. A housing may have a flexible lower surface to reduce loading of the tissue.
Resumen de: WO2025145037A1
Disclosed herein are portable infusion pump systems that provide an ability to simultaneously track insulin on board from insulin deliveries from different sources and/or of different types. A user interface can be provided to enable the user to enter insulin delivered from a source other than the portable infusion pump. A simplified calculation for estimating IOB remaining from each insulin delivery enables such calculations to be carried out with the limited memory and processing capacity of the portable infusion pump.
Resumen de: WO2025140653A1
The present application discloses a measurement method, a system, and a related apparatus. The method is applied to a first electronic device, wherein the first electronic device comprises a first electrode set and a second electrode set; the distance between the first electrode set and the second electrode set is greater than a first distance; and under the condition that the first electrode set and the second electrode set are implanted into subcutaneous tissue, the method comprises: determining a first physiological parameter by means of the first electrode set; and determining an electrocardiogram signal by means of the first electrode set and the second electrode set. In this way, an electrocardiogram signal of a user can be acquired by the first electronic device anytime and anywhere, and any one or more of other physiological parameters (such as blood glucose, blood ketone, blood lactate, and uric acid) of the user can also be measured, thereby improving the health monitoring efficiency.
Resumen de: WO2025140661A1
A blood glucose management method, a user interface, and a related apparatus. The blood glucose management method comprises: on the basis of historical blood glucose levels of a user, determining a first mealtime; on the basis of one or more of a mealtime inputted by the user, and body movements and the heart rate of the user, determining a second mealtime; on the basis of the first mealtime and the second mealtime, determining a third mealtime; and assessing a blood glucose health status of the user by means of the third mealtime. Historical mealtimes of a user that are determined using multiple methods are combined to predict a mealtime of the user, so that an electronic device can more accurately assess a blood glucose situation of the user.
Resumen de: WO2025145056A1
Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.
Resumen de: WO2025140911A1
A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.
Resumen de: WO2025141541A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Resumen de: WO2025145024A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Resumen de: US2019013091A1
User interfaces are needed to alert and inform a person suffering from diabetes or a healthcare provider of possible harmful changes in the patient's blood glucose level. An improved method is presented for issuing an alert regarding a glucose condition of a patient by a diabetes management system. For a given patient, their glucose condition is quantified and presented as a state on a display. Glucose conditions can also be prioritized for a plurality of patients and presented to a healthcare provider.
Resumen de: AU2023415787A1
The present invention provides a sensor applicator assembly for a blood glucose meter, comprising: an applicator; and a body attachment unit which is disposed in the applicator, and which is composed of a housing including an upper frame and a lower frame, wherein the lower frame has a recessed part formed along the entire circumferential section thereof.
Resumen de: WO2025145062A1
Disclosed herein are system, method, and computer program product embodiments for calculating accurate doses for medication using improved user interface features that may be implemented as part of an application operating within a continuous glucose monitoring system. The disclosed interface provides an improved user experience when a medication delivery device is disconnected or does not have the ability to query the requisite data.
Resumen de: US2025218598A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: US2025218565A1
The present disclosure provides a technology capable of appropriately supporting improvement of an individual's lifestyle. The lifestyle improvement support system is provided with an acquisition device capable of acquiring from a target person at least their blood glucose level data, physical activity data, and dietary activity data, as well as a controlling device.
Nº publicación: US2025218600A1 03/07/2025
Solicitante:
SYNCHNEURO INC [US]
SynchNeuro, Inc
Resumen de: US2025218600A1
Glucose forecasting systems and methods that include a minimally invasive scalp-worn behind-the-ear EEG device that includes first and second sensors. With an application on a personal device, analyzing the processed EEG signals with a trained forecasting model and forecasting future glucose levels, of the subject; causing the personal device to visually present on a display information that is indicative of the forecasted future glucose levels.
BOPI
Sede Electrónica
